Gilead Sciences (GILD) just put its HIV prevention portfolio in the spotlight after new PURPOSE 5 trial data showed that twice-yearly lenacapavir kept more people on PrEP and saw no HIV cases over 52 ...
Source LinkGilead Sciences (GILD) just put its HIV prevention portfolio in the spotlight after new PURPOSE 5 trial data showed that twice-yearly lenacapavir kept more people on PrEP and saw no HIV cases over 52 ...
Source Link
Comments